Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling

Area of Science:

• Cardiovascular Biology
• Epigenetics
• Molecular Medicine

Background:

• Ischemic cardiac disease remains a leading global cause of mortality.
• The precise molecular mechanisms driving post-ischemic heart failure (HF) are not fully elucidated.
• Understanding these mechanisms is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To identify molecular alterations in the heart following ischemic injury.
• To investigate the role of chromatin remodeling in the pathogenesis of post-ischemic HF.
• To explore potential therapeutic interventions targeting identified molecular pathways.

Main Methods:

• Utilized in vivo and in vitro experimental models, including human cardiac specimens, a murine HF model, and cellular systems.
• Employed molecular biology techniques to analyze histone modifications and gene expression.
• Assessed the impact of beta-hydroxybutyrate treatment on cellular and molecular parameters.

Main Results:

• Identified a novel epigenetic signature, H3_K27me2K36me1, consistently induced by ischemic injury in all models studied.
• Demonstrated that this histone modification epigenetically represses the master mitochondrial regulator PGC1α.
• Showed that beta-hydroxybutyrate treatment attenuates H3_K27me2K36me1 and improves mitochondrial dysfunction.

Conclusions:

• Maladaptive chromatin remodeling, specifically H3_K27me2K36me1, is a key mechanism in post-ischemic heart injury.
• The repression of PGC1α by this epigenetic modification contributes to mitochondrial dysfunction.
• Ketone bodies represent a promising therapeutic avenue for mitigating ischemic heart injury by modulating metabolism-gene expression pathways.